146 related articles for article (PubMed ID: 17098421)
1. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).
Martoni AA; Pinto C; Di Fabio F; Lelli G; Rojas Llimpe FL; Gentile AL; Mutri V; Ballardini P; Giaquinta S; Piana E
Eur J Cancer; 2006 Dec; 42(18):3161-8. PubMed ID: 17098421
[TBL] [Abstract][Full Text] [Related]
2. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E;
J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
4. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
[TBL] [Abstract][Full Text] [Related]
7. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
8. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Twelves C
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):23-6. PubMed ID: 12520636
[TBL] [Abstract][Full Text] [Related]
9. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
[TBL] [Abstract][Full Text] [Related]
10. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
[TBL] [Abstract][Full Text] [Related]
11. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
[TBL] [Abstract][Full Text] [Related]
13. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
Sastre J; Aranda E; Massutí B; Tabernero J; Chaves M; Abad A; Carrato A; Reina JJ; Queralt B; Gómez-España A; González-Flores E; Rivera F; Losa F; García T; Sanchez-Rovira P; Maestu I; Díaz-Rubio E
Crit Rev Oncol Hematol; 2009 May; 70(2):134-44. PubMed ID: 19111473
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
15. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.
Feliu J; Salud A; Escudero P; Lopez-Gómez L; Bolaños M; Galán A; Vicent JM; Yubero A; Losa F; De Castro J; de Mon MA; Casado E; González-Barón M
Br J Cancer; 2006 Apr; 94(7):969-75. PubMed ID: 16552438
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Gelibter AJ; Gamucci T; Pollera CF; Di Costanzo F; Nuzzo C; Gabriele A; Signorelli C; Gasperoni S; Ferraresi V; Giannarelli D; Cognetti F; Zeuli M
Curr Med Res Opin; 2007 Sep; 23(9):2117-23. PubMed ID: 17651538
[TBL] [Abstract][Full Text] [Related]
17. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
[TBL] [Abstract][Full Text] [Related]
20. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.
Tyagi P; Grothey A
Clin Colorectal Cancer; 2006 Nov; 6(4):261-4. PubMed ID: 17241510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]